RT Journal Article
SR Electronic
T1 Saliva TwoStep for rapid detection of asymptomatic SARS-CoV-2 carriers
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.16.20150250
DO 10.1101/2020.07.16.20150250
A1 Qing Yang
A1 Nicholas R. Meyerson
A1 Stephen K. Clark
A1 Camille L. Paige
A1 Will T. Fattor
A1 Alison R. Gilchrist
A1 Arturo Barbachano-Guerrero
A1 Benjamin G. Healy
A1 Emma R. Worden-Sapper
A1 Sharon S. Wu
A1 Denise Muhlrad
A1 Carolyn J. Decker
A1 Tassa K. Saldi
A1 Erika Lasda
A1 Patrick K. Gonzales
A1 Morgan R. Fink
A1 Kimngan L. Tat
A1 Cole R. Hager
A1 Jack C. Davis
A1 Christopher D. Ozeroff
A1 Gloria R. Brisson
A1 Matthew B. McQueen
A1 Leslie Leinwand
A1 Roy Parker
A1 Sara L. Sawyer
YR 2021
UL http://medrxiv.org/content/early/2021/02/16/2020.07.16.20150250.abstract
AB Here, we develop a simple molecular test for SARS-CoV-2 in saliva based on reverse transcription loop-mediated isothermal amplification (RT-LAMP). The test has two steps: 1) heat saliva with a stabilization solution, and 2) detect virus by incubating with a primer/enzyme mix. After incubation, saliva samples containing the SARS-CoV-2 genome turn bright yellow. Because this test is pH dependent, it can react falsely to some naturally acidic saliva samples. We report unique saliva stabilization protocols that rendered 295 healthy saliva samples compatible with the test, producing zero false positives. We also evaluated the test on 278 saliva samples from individuals who were infected with SARS-CoV-2 but had no symptoms at the time of saliva collection, and from 54 matched pairs of saliva and anterior nasal samples from infected individuals. The Saliva TwoStep test described herein identified infections with 94% sensitivity and >99% specificity in individuals with sub-clinical (asymptomatic or pre-symptomatic) infections.Competing Interest StatementNRM, QY, CLP, SLS are founders of Darwin Biosciences, who licenses the RT-LAMP assay described herein. TKS, EL, and PKG are co-founders of TUMI Genomics, which also has a commercial RT-LAMP test for SARS-CoV-2. R.P. is a co-founder of Faze Medicines.Funding StatementThe pandemic response efforts at the University of Colorado Boulder were supported by CARES act funding from the US government. We thank the Burroughs Wellcome Fund (PATH award to SLS; PDEP award to NRM) and NIH (DP1-DA-046108 to SLS) for funding. This work is also partially supported by the Interdisciplinary Quantitative Biology PhD Program at the BioFrontiers Institute, University of Colorado Boulder.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the University of Colorado Boulder Institutional Review Board. Saliva samples for assay development were collected under protocol 20-0068. Testing on human subjects is aggregated data resulting from University of Colorado Boulder operational COVID-19 surveillance testing.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data is included in the manuscript.